Welcome to our dedicated page for Prestige Consmr Healthcare news (Ticker: PBH), a resource for investors and traders seeking the latest updates and insights on Prestige Consmr Healthcare stock.
The PBH news page on Stock Titan tracks announcements and disclosures from Prestige Consumer Healthcare Inc., a consumer healthcare products company listed on the New York Stock Exchange. Prestige issues frequent press releases covering its over-the-counter (OTC) brand portfolio, financial performance and corporate activities across the U.S. and Canada, Australia, and certain other international markets.
Investors and observers can use this news feed to follow quarterly and annual earnings releases, where Prestige reports revenues, net income, earnings per share, free cash flow, leverage and segment results for its North American OTC Healthcare and International OTC Healthcare businesses. These updates often highlight category trends such as gastrointestinal, women’s health, cough and cold, and eye and ear care, as well as the performance of brands including Monistat®, Summer’s Eve®, Clear Eyes®, Dramamine®, Fleet®, Hydralyte® and others.
The PBH news stream also includes announcements about investor conference participation, such as presentations at consumer staples and consumer growth and e-commerce conferences, and notices of upcoming earnings calls with webcast details. Corporate actions and regulatory topics appear as well, including the voluntary recall by Medtech Products Inc., a Prestige company, of specific lots of Little Remedies® Honey Cough Syrup due to microbial contamination, and communications about strategic transactions like the planned acquisition of Pillar5 Pharma Inc., a sterile ophthalmic manufacturer and Clear Eyes® supplier.
By reviewing the PBH news page regularly, readers can see how Prestige describes its business priorities, category performance, capital allocation decisions such as share repurchases, and developments affecting its OTC healthcare brands and supply chain.
Prestige Consumer Healthcare Inc. (NYSE: PBH) has priced an upsized offering of $600 million in 3.750% senior notes due 2031, to be completed by March 1, 2021. The proceeds will be used to redeem all outstanding 6.375% senior notes due 2024. The offering is being made only to qualified institutional buyers under Rule 144A of the Securities Act. Prestige Consumer Healthcare markets a diverse range of consumer healthcare products across various countries.
Prestige Consumer Healthcare Inc. (NYSE: PBH) announced a private offering of up to $500 million in new senior notes due 2031 through its subsidiary, Prestige Brands, Inc. The funds will be utilized to redeem $600 million of outstanding 6.375% Senior Notes due 2024 and cover related expenses. The redemption is contingent upon the completion of the new notes offering. These notes will be offered only to qualified institutional buyers under Rule 144A and Regulation S of the Securities Act, and it does not constitute an offer to sell or solicit an offer to buy.
Prestige Consumer Healthcare (NYSE:PBH) reported its fiscal Q3 2021 results, highlighting revenues of $238.8 million, a slight decline of 1.1% year-over-year. Despite this, net income grew to $40.9 million, up from $38.1 million, with diluted EPS of $0.81 compared to $0.75 last year. The company raised its full-year revenue outlook to approximately $935 million, driven by steady consumption across key brands and a strategic focus on brand investments. Cash flow also improved, with net cash from operating activities increasing by 10% to $176.5 million for the first nine months.
Prestige Consumer Healthcare Inc. (NYSE:PBH) will release its fiscal 2021 third quarter earnings on February 4, 2021, before market opening. A conference call to discuss these results will follow at 8:30 a.m. ET. U.S. and Canadian participants can call 844-233-9440, while international callers can reach 574-990-1016, using conference ID 4948099. Both a live Internet webcast and an archived replay will be available on the company's Investor Relations page. Prestige markets a diverse portfolio of healthcare products in North America and internationally.
Prestige Consumer Healthcare (PBH) reported Q2 FY2021 revenue of $237.4 million, roughly unchanged from the previous year. Diluted EPS rose to $0.88, a 35% increase compared to $0.65 in Q2 FY2020. The company achieved net income of $44.6 million, a notable uptick from $33.3 million year-over-year. Debt reduction continued with a $74 million paydown this quarter. The FY2021 revenue outlook is approximately $925 million, driven by core brand growth, despite COVID-19-related consumption disruptions.
Prestige Consumer Healthcare Inc. (NYSE:PBH) will release its fiscal 2021 second quarter earnings on November 5, 2020, before market open. A conference call is scheduled for the same day at 8:30 a.m. ET, where management will discuss the results. Participants in the U.S. can dial 844-233-9440 or 574-990-1016 internationally, using conference ID 4199894. This announcement is expected to provide insights into the company's financial performance, including potentially key metrics such as revenue and earnings per share.
Prestige Consumer Healthcare (PBH) reported a 1.2% decrease in revenue to $229.4 million for Q1 FY2021, impacted by COVID-19. Excluding currency effects, the decline was 0.6%. Net income rose to $43.7 million, up from $33.9 million, with diluted EPS increasing 32% to $0.86. Cash from operations was $75.2 million, with non-GAAP free cash flow at $72.6 million. Management anticipates Q2 revenue of at least $225 million and EPS of $0.70 or more, amid ongoing uncertainties.
Prestige Consumer Healthcare (NYSE: PBH) will release its fiscal 2021 first quarter earnings on August 6, 2020, before market opening. The company will host a conference call to discuss the results at 8:30 a.m. ET on the same day, accessible via phone for U.S. and Canadian listeners at 844-233-9440 or 574-990-1016 internationally. A live webcast will be available on the Investor Relations page of the company’s website. Replay options will also be offered for one week post-call.